Tiamenidine

Tiamenidine
Clinical data
Trade names	Sundralen, Symcorad, Symcor
ATC code	C02AC (WHO) ;
Pharmacokinetic data
Elimination half-life	2.3–5 hours
Identifiers
	IUPAC name N-(2-chloro-4-methylthiophen-3-yl)-4,5-dihydro-1H-imidazol-2-amine;
CAS Number	31428-61-2 ;
PubChem CID	39974;
ChemSpider	36548 ;
UNII	195V08O55G;
KEGG	D06127 ;
ChEMBL	ChEMBL295409 ;
CompTox Dashboard (EPA)	DTXSID80185349 ;
Chemical and physical data
Formula	C8H10ClN3S
Molar mass	215.70 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc2scc(c2N/C1=N/CCN1)C;
	InChI InChI=1S/C8H10ClN3S/c1-5-4-13-7(9)6(5)12-8-10-2-3-11-8/h4H,2-3H2,1H3,(H2,10,11,12) ; Key:CVWILQHZFWRYPB-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is an imidazoline compound that shares many of the pharmacological properties of clonidine. It is a centrally-acting α₂ adrenergic receptor agonist (IC₅₀ = 9.1 nM).^[2] It also acts as an α₁-adrenergic receptor agonist to a far lesser extent (IC₅₀ = 4.85 μM).^[2] In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output.^[3] It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis^[4] under the brand name Sundralen^[5] for the management of essential hypertension.^[6]